Truvian Sciences’ Point-of-Care Diagnostics Could Provide Long-Term Solution for Future Pandemics

Hours before the U.S. Food and Drug Administration granted Emergency Use Authorization to California-based Cepheid’s rapid Xpert Xpress SARS-CoV-2 point-of-care diagnostic, Jeff Hawkins, chief executive officer of Truvian Sciences, noted that in all of the industry response to the pandemic, approval of such a device was still missing.